Heart failure (HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart's left ventricle can contract normally but has difficulty relaxing, leading to reduced blood flow and increased pressure in the heart chambers. This condition is significant because it affects a substantial number of older adults and often coexists with other chronic conditions like hypertension and diabetes.
Studies have highlighted that HFpEF is frequently associated with systemic inflammation and vascular dysfunction, which contribute to myocardial stiffness and impaired relaxation. Epidemiological research indicates that HFpEF is more prevalent in women and older individuals, and it carries a higher risk of cardiovascular events and mortality compared to the general population. Treatment strategies often focus on managing underlying conditions and symptoms, as there are currently no specific therapies targeting the core mechanisms of HFpEF.
Inflammation is a key driver of HFpEF, contributing to myocardial dysfunction and remodeling. Additionally, HFpEF significantly increases the risk of cardiovascular disease and mortality. These connections underscore the importance of addressing inflammation and managing comorbidities in patients with HFpEF.
While these findings provide valuable insights, more research is needed to fully understand the complex mechanisms underlying HFpEF and to develop targeted treatments.
Sources
- Heart failure with preserved ejection fraction: everything the clinician needs to know. (PMID:38367642)
- Heart failure with preserved ejection fraction. (PMID:39143132)
- Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. (PMID:34379445)
- Epidemiology of heart failure with preserved ejection fraction. (PMID:28492288)
- A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. (PMID:23684677)
- Evaluation and management of heart failure with preserved ejection fraction. (PMID:32231333)
_Worker-drafted node, Hermes writer enrichment, pending editorial review._
Connections
Heart failure (HFpEF) is a risk factor for
Heart failure (HFpEF) is caused by
Sources
- Heart failure with preserved ejection fraction: everything the clinician needs to know. (2024) pubmed
- Heart failure with preserved ejection fraction. (2024) pubmed
- Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. (2022) pubmed
- Epidemiology of heart failure with preserved ejection fraction. (2017) pubmed
- A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. (2013) pubmed
- Evaluation and management of heart failure with preserved ejection fraction. (2020) pubmed
- Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction. (2025) pubmed
- Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. (2025) pubmed
- Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction. (2025) pubmed
- Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. (2024) pubmed